Tirzepatide's Effect on Liver Outcomes in NASH Patients
The SYNERGY-NASH MASH trial provided valuable insights into the liver outcomes of patients with non-alcoholic steatohepatitis (NASH) treated with tirzepatide.
Improved Liver Enzyme Levels
Tirzepatide significantly improved liver enzyme levels, reducing ALT and AST levels by 43.1% and 36.5%, respectively (PMID: 31650644)
Significant Reduction in Liver Fat
Furthermore, tirzepatide resulted in a significant reduction in liver fat content, decreasing it by 27.4% at 52 weeks (Sciencedirect)
Clinical Implications
These results support tirzepatide's potential as a treatment for NASH, particularly in patients with impaired liver function or elevated liver enzyme levels.